EGFR-inhibitors include EGFR-TKIs, a standard therapy for EGFR-mutated NSCLC, and anti-EGFR antibodies, a standard therapy for CRC, HNSCC, and squamous cell lung cancer [10]. This evidence concerns the gene EGFR and colorectal carcinoma.